Table of Contents
Agenda
Safety Overview
Safety Database
Comparison of Placebo vs. Alefacept Experience
Safety Overview Placebo-Controlled Studies
Safety Overview by Course
Adverse Events ?5% Incidence Placebo-Controlled Studies
Serious Adverse Events
Most Frequent Serious Adverse Events*
Most Frequent Serious Adverse Events*
Deaths
Deaths
Infections
Infections ?5% Incidence
Infections by CD4+ T Cell Counts*
Serious Infections
Serious Skin Infections - All Studies
Infection: Conclusions
Functional Integrity of Immune System
Malignancy
Incidence of Malignancies
Incidence of Malignancies
Single case of B cell lymphoma
Overall Malignancy Rates
Malignancy Conclusions
Percentage Testing Positive for Anti-Alefacept Antibodies
Safety Conclusions
Plans for Extended Long-Term Safety Evaluation
Alefacept Conclusions
Agenda
|